Co-targeting the PI3K and MEK pathways in NSCLC: an in vitro evaluation and mutation prevalence in an Irish patient cohort

被引：0
|
作者：
Heavey, S. [1 ]
Barr, M. P. [1 ,2 ]
Hennessy, B. [3 ]
Toomey, S. [3 ]
Carr, A. [3 ]
Crown, J. [4 ]
Finn, S. [1 ]
Cuffe, S. [1 ,2 ]
O'Byrne, K. J. [5 ]
Gately, K. A. [1 ,2 ]
机构：
[1] Univ Dublin Trinity Coll, Dublin 2, Ireland
[2] St James Hosp, HOPE Directorate, Dublin 8, Ireland
[3] Royal Coll Surgeons Ireland, Dublin 2, Ireland
[4] St Vincents Hosp, Dublin 4, Ireland
[5] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia
来源：
LUNG CANCER | 2014年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [1] CO-TARGETING THE PI3K AND MEK PATHWAYS IN NSCLC: AN IN VITRO EVALUATION AND MUTATION PREVALENCE IN AN IRISH PATIENT COHORT.
    Heavey, Susan
    Barr, Martin
    Hennessy, Brian
    Toomey, Sinead
    Carr, Aoife
    Crown, John
    Davies, Anthony
    O'Byrne, Kenneth
    Gately, Kathy
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1039 - S1039
  • [2] CO-TARGETING THE PI3K-MTOR & MEK PATHWAYS IN NSCLC
    Heavey, S.
    Barr, M.
    Ahmad, A.
    Davies, A.
    O'Byrne, K. J.
    Gately, K. A.
    ANNALS OF ONCOLOGY, 2012, 23 : 69 - 70
  • [3] Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC
    Moore, Gillian
    Lightner, Clara
    Elbai, Samira
    Brady, Lauren
    Nicholson, Siobhan
    Ryan, Ronan
    O'Sullivan, Katie E.
    O'Byrne, Kenneth J.
    Blanco-Aparicio, Carmen
    Cuffe, Sinead
    O'Neill, Michael
    Heavey, Susan
    Finn, Stephen P.
    Gately, Kathy
    CANCERS, 2021, 13 (09)
  • [4] Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC
    Heavey, Susan
    O'Byrne, Kenneth J.
    Gately, Kathy
    CANCER TREATMENT REVIEWS, 2014, 40 (03) : 445 - 456
  • [5] Co-targeting PI3K and ras pathways in trastuzumab resistance.
    Gray, Mike J.
    YangKolodji, Gloria Wangrong
    Tripathy, Debu
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Co-Targeting of the PI3K and RAS Pathways for the Treatment of Carcinoid Tumors
    Valentino, Joseph
    Li, Jing
    Kim, Ji Tae
    Song, Jun
    Mustain, W. C.
    Weiss, Heidi L.
    Anthony, Lowell
    Townsend, Courtney M.
    Evers, B. Mark
    GASTROENTEROLOGY, 2012, 142 (05) : S644 - S644
  • [7] PI3K targeted inhibition in NSCLC: An in vitro evaluation and correlation of mutation status to activated PI3K pathway signaling in NSCLC patients
    Heavey, Susan
    Toomey, Sinead
    Carr, Aoife
    Cuffe, Sinead
    Finn, Stephen
    Hennessy, Bryan
    Crown, John
    Barr, Martin
    O'Byrne, Kenneth
    Gately, Kathy
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [8] Co-targeting the PI3K and androgen receptor signal pathways in castration resistant prostate cancer
    De Velasco, Marco A.
    Kura, Yurie
    Ando, Naomi
    Fukushima, Emiko
    Hatanaka, Yuji
    Yamamoto, Yutaka
    Shimizu, Nobutaka
    Yoshimura, Kazuhiro
    Nozawa, Masahiro
    Yoshikawa, Kazuhiro
    Nishio, Kazuto
    Uemura, Hirotsugu
    CANCER RESEARCH, 2014, 74 (19)
  • [9] Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors.
    Blanco Aparicio, Carmen
    Renner, Oliver
    Gomez-Casero, Elena
    Cebria, Antonio
    Ajenjo, Nuria
    Aguirre, Enara
    Cebrian, David
    Rodriguez de Miguel, Ma Carmen
    Pequeno, Belen
    Isabel Albarran, Ma
    Riesco, Rosario
    Belen Garcia, Ana
    Alvarez, Rosa
    O'Neill, Michael
    Martinez, Sonia
    Pastor, Joaquin
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [10] Targeting of PI3K/AKT and MEK Signaling
    de Bono, J. S.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S84 - S84
12345